Low-dose thiazide diuretics in and around diabetes - Definitely yes, and how do they compare with other interventions?: Guest Editorial

Diabetic Medicine

Volumn 27, Issue 2, 2010, Pages 127-129

  Cruickshank, J K ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; DIABETES MELLITUS; EDITORIAL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; STROKE; COMPLICATION; DIABETIC ANGIOPATHIES; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLUCOSE; HUMANS; HYPERTENSION; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 76249108572     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02932.x     Document Type: Editorial

References (10)

1. Siebenhofer A, Jeitler K, Rakovac I, Horvath K. Diuretics and diabetes incidence - an appeal against the reluctance to prescribe a medication that is safe and proven. Diabet Med 2010 27 : 130 135.
2. Institute for Quality and Efficiency in Health Care in Germany. Vergleichende Nutzenbewertung verschiedener antihypertensiver Wirkstoffe als Therapie der ersten Wahl bei Patienten mit essentieller Hypertonie. IQWiG A05-09. 18-9-2008.
3. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005 95 : 29 35.
4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000 321 : 405 412.
5. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009 52 : 2288 2298.
6. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 : 2545 2559.
7. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 : 2560 2572.
8. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 360 : 129 139.
9. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multi-centre, randomised, open-label trial. Lancet 2009 373 : 2125 2135.
10. Beulens JW, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009 52 : 2027 2036.